Significant weight loss on Ozempic linked to lower risks of obesity-related diseases
People who lost the most weight on Ozempic, Wegovy, Mounjaro, or Saxenda saw major drops in their risk of obesity-related conditions like sleep apnea and kidney disease. Those who gained weight instead faced higher risks, especially for heart failure, even when they stopped taking the drugs within a year. The findings show how much the amount of weight lost matters for your health outcomes on these medications.